FAQs:

Agendia Customer Care is always here to help.  For any additional questions or information, please contact a friendly representative at
888-321-2732

1.  How can I order Agendia testing?

Only a licensed healthcare provider (surgeon, medical oncologist, pathologist) can submit an order request for genomic testing.  Ask your doctor to run the Agendia Breast Cancer Test Suite on your breast cancer.  Local Agendia Oncology Specialists can assist your doctor in getting this done.

2.  Who is eligible for the Agendia Breast Cancer Test Suite?

Patients diagnosed with stage I or II invasive breast carcinoma that is lymph node negative or lymph node positive (up to 3 nodes).  Unlike other assays, there are no restrictions on other factors such as hormone receptor status (ER / HER2).

3.  What will the MammaPrint test results show?

MammaPrint is a 70-gene test that will assess your cancer’s risk of recurrence, or how likely the cancer is to return in the future.  You are given definitive results, either a Low Risk or High Risk result, with no intermediate or undetermined results.  A Low Risk result means you have a 10%, or 1 in 10 chance of your cancer returning.  A High Risk result means you have a 29%, or 3 out of 10 chance of it returning.  These results are based on a 10-year follow- up of a reference group of patients who had no additional treatment.2   A Low Risk result doesn’t guarantee that your cancer will not recur, and a High Risk result doesn’t guarantee that your cancer will.  These results, in addition to all other factors help you and your doctor make the most appropriate breast cancer treatment decisions.

4.  What if I am in the Low Risk group?

If you are in the Low Risk group, you have a lower chance of the cancer returning, and there is little,if any, benefit to getting chemotherapy.  Studies have shown that the addition of hormone therapy alone for ER-positive breast cancer can lower the risk of recurrence by up to 50%.23 

5.  What if I am in the High Risk group?

If you are in the High Risk group, the addition of chemotherapy may be considered as part of your treatment plan. High Risk patients can be further divided into subtypes, which can refine your treatment plan. These subtypes provide additional information about what your tumor may respond to best: hormone therapy, chemotherapy, targeted therapy or a combination.

6.  What will the BluePrint results show?

BluePrint is an 80-gene test that uncovers your tumor’s functional molecular subtype.  Molecular subtyping informs your doctor about how the tumor is functioning underneath the surface.  Traditional subtyping (such as IHC or FISH) assess a tumor by looking at cell surface characteristics, while molecular subtyping looks deeper at the functional level, to see which genes are driving the tumor’s behavior. Combined with MammaPrint, BluePrint will determine if your breast cancer is Luminal-type(A or B), Basal-type, or HER2-type.  These findings are important when deciding which treatment is most appropriate for your specific tumor

7.  Why should I use MammaPrint and BluePrint together?

MammaPrint and BluePrint provide you and your doctor deeper insight into tumor pathways, uncovering your hidden tumor biology.  By combining  risk of recurrence, with molecular subtyping, you get a clearer picture of how your breast cancer is functioning, leading to more informed treatment decision making.  MammaPrint is the first FDA- cleared breast cancer recurrence assay, and is the only breast cancer recurrence assay backed by peer-reviewed, prospective outcome data.1   BluePrint molecular subtyping is the most widely available molecular subtyping assay that helps identify your potential level of responsiveness to chemotherapy more accurately than IHC/FISH, with better correlation to long-term clinical treatment outcomes.10

8.  Will my insurance cover the cost of the test?

Agendia is in network with Medicare and many large national and regional health plans, covering over 200 million lives in the United States.  Agendia will bill your insurance company directly (throughout the US). Based on your specific benefit level, the insurance company may choose to pay a portion or all of the cost of the tests run by Agendia. You may be responsible for any co-insurance, co-pay, or deductible, per your health insurance plan terms.  Please call us and our dedicated patient advocates will work with you and your insurance to find out your specific coverage details.  Agendia’s Patient Advocates can be reached at 888-363-7868 or by email at billing@agendia.com.

9.  What if I don’t have insurance or my health plan won’t cover the test?

Agendia is a compassionate company offering a wide range of financial assistance programs such as:

  • Interest-free payment plans
  • Uninsured / Underinsured patient assistance
  • Indigent patient assistance

For more information, or to speak with a Patient Advocate Representative about your specific situation, call us at 888-363-7868 or email at billing@agendia.com.

10.  How long does it take to get results?

On average, results are provided within 10 business days.

What is genomic testing?

Genomic tests look at your specific tumor’s genes, to help find out what’s driving its growth.  Using gene expression testing to help design a tailored treatment plan is called personalized medicine.  These are not the same as genetic tests that determine your inherited risk or hereditary predisposition for cancer.

Your physician will assess many factors prior to determining your treatment plan, including the size of the tumor, lymph node involvement, and the hormone receptor status of your cancer.  These factors, along with your tumor’s genomic profile, can help you and your physician make the most informed treatment decisions for your specific type of cancer.

Your tumor is unique, your treatment should be too

  • Julieta

    Julieta was originally told she needed chemotherapy but wanted to avoid it.

    Share This Video

    Julieta

    Julieta was originally told she needed chemotherapy but wanted to avoid it.

    Share This Video

  • Mary

    Mary is confident knowing that she really needed chemotherapy.

    Share This Video

    Mary

    Mary is confident knowing that she really needed chemotherapy.

    Share This Video

  • Nicole

    Nicole talks about how MammaPrint may have saved her life by letting her doctors know that her tumor was high risk even though it appeared to be low risk by traditional parameters.

    Share This Video

    Nicole

    Nicole talks about how MammaPrint may have saved her life by letting her doctors know that her tumor was high risk even though it appeared to be low risk by traditional parameters.

    Share This Video

  • Dealing with an "intermediate" breast cancer recurrence score

    Breast cancer patient Cari G. explains how MammaPrint’s definitive results helped her and her physician choose the best course of treatment when she was initially given an ambiguous Intermediate result from the 21-gene assay

    Share This Video

    Dealing with an "intermediate" breast cancer recurrence score

    Breast cancer patient Cari G. explains how MammaPrint’s definitive results helped her and her physician choose the best course of treatment when she was initially given an ambiguous Intermediate result from the 21-gene assay

    Share This Video

  • Sherri

    Sherri found it reassuring when her MammaPrint test came back and showed that she had a low risk of recurrence.

    Share This Video

    Sherri

    Sherri found it reassuring when her MammaPrint test came back and showed that she had a low risk of recurrence.

    Share This Video

  • Breast cancer is heterogeneous disease

    Dr. Rene Bernards, PhD, co-developer of MammaPrint® discusses how breast cancer biology drove the discovery of the 70-Gene Breast Cancer Recurrence Assay

    Share This Video

    Breast cancer is heterogeneous disease

    Dr. Rene Bernards, PhD, co-developer of MammaPrint® discusses how breast cancer biology drove the discovery of the 70-Gene Breast Cancer Recurrence Assay

    Share This Video

JOIN A SUPPORT GROUP

Learn more about breast cancer treatment by visiting www.knowyourbreastcancer.com or connect with a support group through the Symphony Sisterhood on Facebook